It was found that the expression level of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) has significant changes during ischemic stroke. Further studies suggest that UCHL1 is a potential biomarker of ischemic stroke. It is involved in regulating and maintaining brain function through multiple pathways. On the one hand, it is an important component of the ubiquitin proteasome pathway (UPP), which removes abnormal proteins from neurons while preventing the accumulation of toxic proteins. On the other hand, it participates in regulating oxidative damage, neuroinflammation, and motor pathways. However, its specific mechanism of action in stroke pathology is unclear. Therefore, in order to explore the specific role of UCHL1 in stroke pathology, Ace Therapeutics provides comprehensive services to promote the understanding of stroke and also to facilitate the development of stroke therapies targeting UCHL1.
Given that ischemic stroke can impair UPP function through the production of reactive oxygen species such as nitric oxide, superoxide, and reactive lipid species such as isoprostanes, levogranidin, and cyclopentenone prostaglandins, and other pathways. However, the role played by UCHL1, a major component of the UPP, is not well understood. Therefore, Ace Therapeutics provides comprehensive services to explore the role played by UCHL1 as a major component of UPP in ischemic stroke.
In view of the complex function of UCHL1 in stroke, Ace Therapeutics also provides comprehensive services to explore in depth its other functions in stroke.
You are free to customize the testing services you need or let our professional scientists optimize and implement the complete experimental methods for you. If you would like to learn more about our services, please feel free to contact us.
We are committed to accelerating progress in stroke research and drug development.